Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab resulted in a significant improvement, as compared with neoadjuvant chemotherapy alone, in overall survival among patients with early-stage triple-negative breast cancer. (Funded by Merck Sharp and Dohme, a subsidiary of Merck [Rahway, NJ]; KEYNOTE-522 ClinicalTrials.gov number, NCT03036488.).
Authors
- Michael Untch (ORCID: https://orcid.org/0000-0002-1233-1267)
- Rina Hui (ORCID: https://orcid.org/0000-0003-0696-7442)
- Heather L. McArthur (ORCID: https://orcid.org/0000-0002-0201-3871)
- Masato Takahashi (ORCID: https://orcid.org/0000-0002-6641-9598)
- Peter A. Fasching (ORCID: https://orcid.org/0000-0003-4885-8471)
- Lajos Pusztai (ORCID: https://orcid.org/0000-0001-9632-6686)
- Fátima Cardoso (ORCID: https://orcid.org/0000-0002-6692-2249)
- Nadia Harbeck (ORCID: https://orcid.org/0000-0002-9744-7372)
- Gursel Aktan
- Carsten Denkert (ORCID: https://orcid.org/0000-0002-2249-0982)
- Joyce O’Shaughnessy (ORCID: https://orcid.org/0000-0002-2955-5523)
- Rebecca Dent (ORCID: https://orcid.org/0000-0001-6421-7602)
- Peter Schmid
- Theodoros Foukakis (ORCID: https://orcid.org/0000-0001-8952-9987)
- Seock‐Ah Im (ORCID: https://orcid.org/0000-0002-5396-6533)
- Marie‐Ange Mouret‐Reynier (ORCID: https://orcid.org/0000-0001-5542-5813)
- Xuan Zhou (ORCID: https://orcid.org/0000-0003-3919-0342)
- Vassiliki Karantza (ORCID: https://orcid.org/0000-0003-4017-7858)
- Yeon Hee Park (ORCID: https://orcid.org/0000-0003-4156-9212)
- Marta Ferreira (ORCID: https://orcid.org/0000-0002-9064-4859)
- Javier Cortes
- Sherko Kümmel
- Konstantinos Tryfonidis
Institutions
- Champalimaud Foundation (PT)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Karolinska University Hospital (SE)
- Philipps University of Marburg (DE)
- Queen Mary University of London (GB)
- Cancer Institute of New South Wales (AU)
- Samsung Medical Center (KR)
- Baylor University Medical Center (US)
- Yale Cancer Center (US)
- Seoul National University Hospital (KR)
- Karolinska Institutet (SE)
- National Cancer Centre Japan (JP)
- Universitätsklinikum Erlangen (DE)
- IPO Porto (PT)
- Breast Center (CH)
- Centre Jean Perrin (FR)
- National Cancer Centre Singapore (SG)
- Hokkaido University Hospital (JP)
- Kliniken Essen-Mitte (DE)
- Comprehensive Cancer Center Erlangen (DE)
- Helios Hospital Berlin-Buch (DE)
- Ludwig-Maximilians-Universität München (DE)
- Sungkyunkwan University (KR)
- The University of Texas Southwestern Medical Center (US)
- University of Hong Kong (HK)
- Universidad Europea de Madrid (ES)
Publication Details
- Journal
- New England Journal of Medicine
- Published
- 2024-09-15
- DOI
- https://doi.org/10.1056/nejmoa2409932
- Citations
- 335
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 95.52
Funders
- Merck